Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion ...

(Reuters) -Vertex Pharmaceuticals' experimental drug reduced acute, post-surgical pain without the risk of addiction, a major milestone in the company's decades-long efforts to bring a non-opioid ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The FDA approved Vertex Pharmaceuticals' Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, studies show it's only modestly effective compared to opioid ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex Pharmaceuticals' experimental drug reduced acute, post-surgical pain without the risk of addiction, a major milestone in the company's decades-long efforts to bring a non-opioid pain ...